Fms样酪氨酸激酶3
基因组不稳定性
综合征如奈梅亨破损综合症
癌症研究
DNA损伤
蛋白激酶B
生物
髓系白血病
信号转导
细胞生物学
突变
遗传学
DNA
基因
共济失调毛细血管扩张
作者
Annahita Sallmyr,Jinshui Fan,Kamal Datta,Kyu-Tae Kim,Dan Grosu,Paul S. Shapiro,Donald Small,Feyruz Virgilia Rassool
出处
期刊:Blood
[Elsevier BV]
日期:2008-01-11
卷期号:111 (6): 3173-3182
被引量:334
标识
DOI:10.1182/blood-2007-05-092510
摘要
Activating mutations of the FMS-like tyrosine kinase-3 (FLT3) receptor occur in approximately 30% of acute myeloid leukemia (AML) patients and, at least for internal tandem duplication (ITD) mutations, are associated with poor prognosis. FLT3 mutations trigger downstream signaling pathways including RAS-MAP/AKT kinases and signal transducer and activator of transcription-5 (STAT5). We find that FLT3/ITD mutations start a cycle of genomic instability whereby increased reactive oxygen species (ROS) production leads to increased DNA double-strand breaks (DSBs) and repair errors that may explain aggressive AML in FLT3/ITD patients. Cell lines transfected with FLT3/ITD and FLT3/ITD-positive AML cell lines and primary cells demonstrate increased ROS. Increased ROS levels appear to be produced via STAT5 signaling and activation of RAC1, an essential component of ROS-producing NADPH oxidases. A direct association of RAC1-GTP binding to phosphorylated STAT5 (pSTAT5) provides a possible mechanism for ROS generation. A FLT3 inhibitor blocked increased ROS in FLT3/ITD cells resulting in decreased DSB and increased repair efficiency and fidelity. Our study suggests that the aggressiveness of the disease and poor prognosis of AML patients with FLT3/ITD mutations could be the result of increased genomic instability that is driven by higher endogenous ROS, increased DNA damage, and decreased end-joining fidelity.
科研通智能强力驱动
Strongly Powered by AbleSci AI